Sarepta Therapeutics | SRPT - Sales Revenues


Sarepta Therapeutics reported $401.3M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amgen USD 10.1B 1.48B Jun/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
Biogen USD 2.74B 490M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Capricor Therapeutics USD 11.13M 8.87M Dec/2024
Daiichi Sankyo JPY 574.74B 12.26B Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
Incyte USD 1.67B 400M Jun/2026
Insmed USD 425.49M 119.53M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
Moderna USD 100M 289M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Novavax USD 147.14M 76.69M Dec/2025
Pfizer USD 15.03B 530M Jun/2026
PTC Therapeutics USD 361M 88M Jun/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.95B 710M Jun/2026
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026